Venus, Saturn and the moon dazzle at dawn in 'romantic' photo from Chew Valley Lake (photo)
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Astrophotographer Josh Dury captured a stunning celestial scene early Friday morning (May 23), as the planets Venus and Saturn aligned with the thin waning crescent moon above the still waters of Chew Valley Lake, Somerset, U.K.
The image was taken at 4 a.m. BST (11 p.m. EDT / 03:00 GMT) and showcases a fleeting "celestial triangle" that appeared just before sunrise.
"The planets Saturn, Venus and the waning crescent moon formed a beautiful cosmic display," Dury told Space.com in an email.
This cosmic meetup unfolded in the quiet moments before dawn, with Venus shining brightly just below the moon and Saturn positioned higher in the sky. The peaceful lake and early morning mist offered the perfect foreground.
"For this scene, I had drawn attention to a simple, natural composition," Dury said. "Picture the scene at dawn break; rolling mist over the Great Lake, the sound of a distant cuckoo fills the air and water so still — it was like a mirror. All together, making for an overly romantic scene that lasted only for a matter of minutes before the light of dawn emerged."
Image 1 of 2
Image 2 of 2
Dury used a Sony A7S II camera with a Sigma 85mm F/1.4 Art lens mounted on a Benro Tortoise Tripod to capture the shot.
If you missed this early morning display, don't worry: You still have a chance to catch a similar view early Saturday (May 24), when the crescent moon shifts to Venus' left, with Saturn positioned higher to the right.
If you're looking for a telescope or binoculars to observe the night sky, our guides for the best binoculars deals and the best telescope deals now can help. Our best cameras for astrophotography and best lenses for astrophotography can help you get ready to capture the next stunning skywatching event.
Editor's Note: If you snap an awesome astrophoto and would like to share it with Space.com's readers, send your photo(s), comments, and your name and location to spacephotos@space.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
MHRA Urges Contraception With GLP-1 Weight-Loss Drugs
The Medicines and Healthcare products Regulatory Agency (MHRA) has reiterated that women using weight-loss drugs must use effective contraception, as the risks of these drugs to a foetus remain unclear. The warning follows concerns that some users in the UK may not be taking glucagon-like peptide-1 receptor agonists (GLP-1s) safely. To date, the MHRA has received more than 40 reports relating to pregnancies in women taking these medications. 'These medicines must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding,' the MHRA stated. Women who become pregnant while using these drugs should stop treatment immediately and consult a healthcare professional. There is not enough safety data to determine if the drugs could harm a developing baby, the agency said. Avoid Unregulated Sellers, MHRA Warns The MHRA also warned against buying these drugs from unregulated sources such as beauty salons or via social media. 'Not only does this expose people wanting to lose weight to serious health risks, it is also against the law to sell these medicines in this way,' said Dr Alison Cave, the MHRA's chief safety officer. The agency emphasised that weight-loss drugs should not be taken without first consulting a healthcare professional. 'The only way to guarantee receiving a genuine GLP-1 medicine is to obtain it from a legitimate pharmacy,' Cave said. Pharmacies Seeing High Demand 'Community pharmacies have been experiencing unprecedented levels of interest for weight loss injections,' said Jasmine Shah, medication safety officer at the National Pharmacy Association. 'It is therefore important that regulations and guidance keep pace with this demand.' Mounjaro May Lower Effectiveness of Oral Contraceptives The MHRA noted that Mounjaro (tirzepatide) may reduce the effectiveness of oral contraceptives in people with overweight or obesity. Women taking Mounjaro should use a non-oral contraceptive method for 4 weeks after starting the drug and for 4 weeks after any dose increase. This advice applies only to Mounjaro users. Patients are also advised to be alert for signs of acute pancreatitis. Risks in Pregnancy Remain Unclear 'There is hardly any available data from human studies to be able to advise if these weight loss drugs are safe in pregnancy,' said Rebecca Reynolds, professor of metabolic medicine at the University of Edinburgh. 'The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans,' she told the Science Media Centre (SMC). Dr Bassel Wattar, consultant obstetrician and gynaecologist at Epsom and St Helier University Hospitals, supported the MHRA's warning. 'There is some data from animal studies suggesting there is a risk of malformation to the foetus — in animals falling pregnant while taking GLP-1 agonists — but data remains limited in humans,' he said. However, Dr Caroline Ovadia, senior clinical lecturer in obstetrics at the University of Edinburgh, noted to the SMC that existing human cohort studies had not shown clear evidence of harm. Online Buyers May Miss Safety Guidance Although direct evidence linking GLP-1 drugs to contraceptive failure is limited, the high number of users means even a small risk could have public health implications, experts warned. Professor Ying Cheong, consultant in reproductive medicine at the University of Southampton, speaking to the SMC, said that gastrointestinal side effects, such as vomiting and diarrhoea, could impair oral contraceptive absorption, increasing the risk of unintended pregnancy. 'Many people are buying weight loss drugs online and so may not receive this important advice about contraception,' Reynolds pointed out. 'These are not harmless lifestyle drugs,' stressed Cheong. 'The public urgently needs to understand that these medications require proper medical supervision to avoid unintended harm, particularly to reproductive health.'
Medscape
6 hours ago
- Medscape
Walking Speed Test Predicts Heart Risk Pre–Kidney Transplant
A simple test of walking speed before kidney transplant could predict the risk for mortality and cardiovascular events, enabling clinicians to quickly activate patients with good cardiovascular fitness and target further screening or prehabilitation to those who need it. METHODOLOGY: Researchers retrospectively studied 995 patients (median age, 56 years; 36% women) assessed for kidney transplant at the Royal Free London NHS Foundation Trust from June 2014 to August 2022 to determine whether a simple walking speed test could predict the likelihood of abnormal cardiac stress test results and posttransplant outcomes. Walking speed was assessed by timing patients as they walked 130 m along a hospital corridor — walking to the end, touching the wall at the end of the corridor, and returning to the start point — as fast as they could; participants were then stratified into four quartiles based on the walking speed from fastest (> 1.83 m/sec) to slowest (< 1.35 m/sec). Pretransplant cardiovascular testing included stress echocardiography or myocardial perfusion scanning, with cardiovascular events defined as non–ST-elevation myocardial infarction, ST-elevation myocardial infarction, and cerebrovascular events. The mean follow-up duration was 54.2 months. TAKEAWAY: The mean time to complete the walking test was 86.9 seconds; 89 patients were unable to complete the test. Patients in the fastest walking quartile had significantly lower rates of cardiac events (1.62% vs 10.6%) and mortality (5.3% vs 27.9%) and a higher rate of activation for transplant (90.6% vs 55.3%) than those in the slowest walking quartile ( P < .001 for all). < .001 for all). Patients in the fastest walking quartile also had a lower rate of abnormal cardiac stress test results and a reduced need for coronary angiography, with none requiring coronary intervention prior to activation. Walking time was a significant predictor of cardiac events ( P = .048) with a high negative predictive value (86.2%) for stress test outcomes. IN PRACTICE: "Our study would suggest that a simple and low cost evaluation of walking speed may predict outcomes in patients being evaluated for kidney transplant and provide a good screening test to avoid significant cardiac work up in fitter patients, thus allowing greater scrutiny, with or without attempts to improve cardiovascular reserve, in patients with poorer exercise capacity," the authors wrote. SOURCE: This study was led by Pranav Satish of the Royal Free Hospital, Pond Street, London, England. It was published online on May 29, 2025, in Nephrology Dialysis Transplantation . LIMITATIONS: T he study's retrospective design and a single assessment of walking speed at the initial evaluation, rather than repeated measures, may have limited the interpretation of the findings. This study did not account for possible changes in walking speed before or after the assessment, which may have affected the reliability of the results. Although the 130-m timed corridor walk test provided a rapid assessment of the cardiorespiratory reserve, it is not internationally standardised. DISCLOSURES: This study received no financial support . The authors declared no conflicts of interest.
Medscape
6 hours ago
- Medscape
IL-23 Inhibitors Show Highest Drug Survival in Psoriasis
Interleukin (IL)-23p19 inhibitors guselkumab and risankizumab demonstrated the highest drug survival for effectiveness and safety comparable with ustekinumab over 2 years, exceeding that of all other biologics. IL-17 receptor inhibitor brodalumab showed comparable effectiveness and safety with adalimumab and secukinumab. METHODOLOGY: Researchers conducted a cohort study using data from the British Association of Dermatologists Biologics and Immunomodulators Register from November 2007 to June 2023 and compared the drug survival of all current commonly used biologics in patients with chronic plaque psoriasis (median age at therapy initiation, 48 years). The analysis included 19,034 treatment courses across the following biologics: Tumour necrosis factor-alpha inhibitor adalimumab (n = 6815), IL-12/23p40 inhibitor ustekinumab (n = 5639), IL-17A inhibitors secukinumab (n = 3051) and ixekizumab (n = 1072), IL-17 receptor inhibitor brodalumab (n = 367), and IL-23p19 inhibitors guselkumab (n = 1258) and risankizumab (n = 832). Multivariable flexible parametric models assessed drug survival, with discontinuation due to ineffectiveness and adverse effects reported separately. Researchers also calculated the restricted mean survival time (RMST) at 2 years for each biologic and the difference in RMST between all comparator biologics. The overall median follow-up duration was 2.3 years. TAKEAWAY: Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the highest survival for safety (1.94 years; 95% CI, 1.92-1.96 years), followed by guselkumab (1.92 years; 95% CI, 1.90-1.94 years) and ustekinumab (1.92 years; 95% CI, 1.91-1.93 years). Brodalumab exhibited a lower adjusted survival time for effectiveness (1.75 years; 95% CI, 1.69-1.81 years) than most biologics except secukinumab and adalimumab and lower drug survival for safety than all biologics except the IL-17A inhibitors and adalimumab. Among the IL-17A inhibitors, secukinumab exhibited significantly lower adjusted drug survival than ixekizumab for effectiveness but had a significantly higher safety profile. Prior exposure to biologics was associated with a decline in survival, with significantly larger reductions observed for IL-17 inhibitors. IN PRACTICE: "Drug survival is high with IL23p19 inhibitors. People with psoriasis persist with IL23p19 inhibitors up to an estimated 21 weeks more for effectiveness and 13 weeks more for safety compared with other biologics over a 2-year period on average," the authors wrote. "This evidence on the absolute difference in time persisted on biologic may help clinicians and patients make an informed decision on choosing the right biologic, including differentiating between different classes of biologics based on the patient's history of having PsA [psoriatic arthritis] or not, their treatment history, and whether they prioritize treatment longevity," they added. SOURCE: This study was led by Leila Motedayen Aval, The University of Manchester, The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England. It was published online on May 29, 2025, in the Journal of the European Academy of Dermatology and Venereology . LIMITATIONS: This study was limited by missing data for newer biologics, particularly IL-17A inhibitors and IL-23p19 inhibitors, and shorter follow-up periods for newer treatments. Residual selection bias may have been present. Additionally, researchers could not evaluate dosing regimens due to missing data for over 50% of dosing frequency information for secukinumab, and results may not be generalisable beyond the UK and Republic of Ireland healthcare systems. DISCLOSURES: The British Association of Dermatologists Biologic Register Ltd receives income from AbbVie, Almirall, Eli Lilly, J&J, Leo Pharma, Novartis, Samsung Bioepis, UCB, BI, and BMS for providing pharmacovigilance services. This research was supported by the National Institute for Health and Care Research Manchester, Guy's and St Thomas' and Newcastle's Biomedical Research Centres. Several authors reported receiving grants or personal fees and having other ties with various sources.
